Regentis Biomaterials Targets $3 Billion Cartilage Repair Market with GelrinC

Regentis Biomaterials (NYSE American: RGNT) is making waves in the orthopedic space with its advanced cartilage regeneration platform, GelrinC. The company is targeting a massive $3 billion U.S. cartilage repair market, supported by approximately 470,000 annual knee cartilage repair procedures and a growing demand for regenerative medicine. As healthcare shifts toward therapies that restore damaged tissue rather than just manage symptoms, Regentis is poised to address one of orthopedic medicine’s largest unmet needs: cartilage defects that cause pain, reduced mobility, and degenerative joint disease.

GelrinC is a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment. Unlike traditional approaches, GelrinC requires no cell harvesting, laboratory expansion, patient-specific manufacturing, or a second surgery. Its single-step, approximately 10-minute procedure fits seamlessly into current surgical workflows, aiming to improve patient outcomes and support durable cartilage repair. The company's broader mission is to establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies. Clinical data generated so far underscores its potential to transform how surgeons and patients approach cartilage damage.

This news release was disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid marketing engagement with IBN.Ai, a specialized communications platform. NetworkNewsWire (“NNW”) is also involved in the distribution, leveraging its extensive network of wire solutions, editorial syndication to 5,000+ outlets, and social media distribution to reach a wide audience. For investors, the latest updates on RGNT are available at https://nnw.fm/RGNT. This partnership highlights the growing interest in regenerative medicine and the potential for Regentis to disrupt the cartilage repair market.